• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司帕沙星与环丙沙星治疗复杂性尿路感染的疗效比较

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.

作者信息

Naber K G, di Silverio F, Geddes A, Guibert J

机构信息

Urologic Clinic, Elisabeth Hospital, Straubing, Germany.

出版信息

J Antimicrob Chemother. 1996 May;37 Suppl A:135-44. doi: 10.1093/jac/37.suppl_a.135.

DOI:10.1093/jac/37.suppl_a.135
PMID:8737133
Abstract

A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days. Urinary tract infection was defined as pyuria and bacteriuria (cfu > or = 10(5)/mL). Evaluations were performed at four time-points. The clinical efficacy of the two antibacterial agents was equivalent at the end of treatment: clinical cure in 88.6% of the intent-to-treat population and 87.3% in the evaluable population treated with sparfloxacin compared to 85.4% and 84.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The clinical results were also equivalent at follow-up. The bacteriological efficacy of the two agents was not equivalent. At the end of treatment, bacteriological cure was observed in 72.6% of the intent-to-treat and 72.1% of the evaluable populations treated with sparfloxacin and in 81.4% and 80.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The difference was primarily because of a higher number of persisting pathogens, which included Enterobacteriaceae other than Escherichia coli, Pseudomonas aeruginosa and enterococci, which exhibited moderate susceptibility to sparfloxacin. Tolerability was similar in the two treatment groups.

摘要

共有686例患有复杂性尿路感染的成年患者参加了一项双盲、随机、多中心研究,以比较司帕沙星(第1天给予200mg负荷剂量,随后每日100mg)与环丙沙星(每日口服500mg,分两次)治疗10至14天的效果。尿路感染定义为脓尿和菌尿(菌落形成单位>或=10⁵/mL)。在四个时间点进行评估。两种抗菌药物在治疗结束时临床疗效相当:在意向性治疗人群中,司帕沙星治疗组的临床治愈率为88.6%,可评估人群中为87.3%;相比之下,环丙沙星治疗组在意向性治疗人群和可评估人群中的临床治愈率分别为85.4%和84.8%。随访时临床结果也相当。两种药物的细菌学疗效不相当。治疗结束时,司帕沙星治疗的意向性治疗人群和可评估人群中细菌学治愈率分别为72.6%和72.1%,环丙沙星治疗的意向性治疗人群和可评估人群中分别为81.4%和80.8%。差异主要是由于持续存在的病原体数量较多,其中包括除大肠杆菌外的肠杆菌科细菌、铜绿假单胞菌和肠球菌,这些病原体对司帕沙星表现出中度敏感性。两个治疗组的耐受性相似。

相似文献

1
Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.司帕沙星与环丙沙星治疗复杂性尿路感染的疗效比较
J Antimicrob Chemother. 1996 May;37 Suppl A:135-44. doi: 10.1093/jac/37.suppl_a.135.
2
Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.司帕沙星与环丙沙星治疗女性社区获得性急性单纯性尿路感染的比较。司帕沙星多中心单纯性尿路感染研究组。
Clin Ther. 1999 Jun;21(6):966-81. doi: 10.1016/s0149-2918(99)80018-6.
3
A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.洛美沙星与环丙沙星治疗复杂性或复发性尿路感染的安全性及疗效比较。
Am J Med. 1992 Apr 6;92(4A):82S-86S. doi: 10.1016/0002-9343(92)90315-3.
4
Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men.单次口服司帕沙星与环丙沙星治疗男性急性淋菌性尿道炎的疗效及安全性比较
J Antimicrob Chemother. 1996 May;37 Suppl A:115-22. doi: 10.1093/jac/37.suppl_a.115.
5
Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.司帕沙星与环丙沙星治疗社区获得性复杂性皮肤及皮肤结构感染的比较
Clin Ther. 1999 Apr;21(4):675-90. doi: 10.1016/S0149-2918(00)88319-8.
6
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.洛美沙星与环丙沙星治疗慢性细菌性前列腺炎的比较。
Int J Antimicrob Agents. 2002 Jul;20(1):18-27. doi: 10.1016/s0924-8579(02)00067-5.
7
Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.每日一次芦氟沙星与每日两次环丙沙星治疗急性单纯性肾盂肾炎患者的对比研究
J Urol. 1995 Jul;154(1):19-24.
8
A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.一项比较低剂量、短疗程环丙沙星与标准7天复方新诺明或呋喃妥因疗法治疗单纯性尿路感染的试验。
J Antimicrob Chemother. 1999 Mar;43 Suppl A:67-75.
9
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.司帕沙星与氧氟沙星治疗社区获得性急性单纯性尿路感染。司帕沙星多中心泌尿道感染研究组。
Antimicrob Agents Chemother. 1998 Sep;42(9):2262-6. doi: 10.1128/AAC.42.9.2262.
10
Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.普卢利沙星与环丙沙星治疗成人复杂性尿路感染的比较。
Urol Int. 2005;74(4):326-31. doi: 10.1159/000084432.

引用本文的文献

1
The new fluoroquinolones: A critical review.新型氟喹诺酮类药物:批判性综述。
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
2
Complicated urinary tract infection in adults.成人复杂性尿路感染。
Can J Infect Dis Med Microbiol. 2005 Nov;16(6):349-60. doi: 10.1155/2005/385768.
3
Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.抗菌药物的药代动力学特征与尿脓毒症的优化治疗
Clin Pharmacokinet. 2007;46(4):291-305. doi: 10.2165/00003088-200746040-00003.
4
Quinolones for uncomplicated acute cystitis in women.喹诺酮类药物用于治疗女性单纯性急性膀胱炎。
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD003597. doi: 10.1002/14651858.CD003597.pub2.
5
Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.氟喹诺酮类药物在严重细菌性尿路感染治疗中的作用。
Drugs. 2004;64(12):1359-73. doi: 10.2165/00003495-200464120-00007.
6
Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study.厄他培南与头孢曲松随后联合适当口服疗法治疗成人复杂性尿路感染:一项前瞻性、随机、双盲多中心研究的结果
Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900. doi: 10.1128/AAC.46.9.2895-2900.2002.
7
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.司帕沙星与氧氟沙星治疗社区获得性急性单纯性尿路感染。司帕沙星多中心泌尿道感染研究组。
Antimicrob Agents Chemother. 1998 Sep;42(9):2262-6. doi: 10.1128/AAC.42.9.2262.